Literature DB >> 11213934

The tripeptide glycyl-prolyl-glycine amide does not affect the early steps of the human immunodeficiency virus type 1 replication.

J Su1, M H Naghavi, A Jejcic, P Horal, Y Furuta, Y P Wu, S L Li, W W Hall, L Goobar-Larsson, B Svennerholm, A Vahlne.   

Abstract

OBJECTIVE: To determine whether the peptide glycyl-prolyl-glycine amide (GPG-NH2) corresponding to a conserved motif in the tip of the third hypervariable region of gp120 affected the early events in the human immunodeficiency virus type 1 (HIV-1) replication. DESIGN/
METHODS: Glycyl-prolyl-glycine amide was tested for its effect on HIV-1 adsorption, co-receptor usage, proviral DNA synthesis, messenger RNA (mRNA) synthesis and splicing, translation, tat/TAR transactivation, and virus protease activity.
RESULTS: Glycyl-prolyl-glycine amide did not appear to affect the early events of the virus replication. HIV-1 having glycine-leucine-glycine instead of GPG in the V3 loop and the mutants deleted of the GPG motif were still inhibited by the peptide. Glycyl-prolyl-glycine-NH2 had no discernible effect on any of the other steps in the virus replication cycle tested. The only effect observed was an increased sodium dodecyl sulfate polyacrylamide amide gel electrophoresis mobility of gp160/120 at high concentrations of GPG-NH2.
CONCLUSIONS: The tripeptide GPG-NH2 is a nontoxic compound that inhibits the replication of HIV-1 by an apparently new mode of action.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11213934

Source DB:  PubMed          Journal:  J Hum Virol        ISSN: 1090-9508


  4 in total

1.  Orally active antiviral tripeptide glycyl-prolyl-glycinamide is activated by CD26 (dipeptidyl peptidase IV) before transport across the intestinal epithelium.

Authors:  Ina Hubatsch; Lucia Lazorova; Anders Vahlne; Per Artursson
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

2.  Tripeptide interference with human immunodeficiency virus type 1 morphogenesis.

Authors:  Stefan Höglund; Jin Su; Sara Sandin Reneby; Akos Végvári; Stellan Hjertén; Ida-Maria Sintorn; Hillary Foster; Yi-Pyng Wu; Ingela Nyström; Anders Vahlne
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

3.  Small molecule targets Env for endoplasmic reticulum-associated protein degradation and inhibits human immunodeficiency virus type 1 propagation.

Authors:  Alenka Jejcic; Robert Daniels; Laura Goobar-Larsson; Daniel N Hebert; Anders Vahlne
Journal:  J Virol       Date:  2009-07-29       Impact factor: 5.103

4.  Activity of the small modified amino acid alpha-hydroxy glycineamide on in vitro and in vivo human immunodeficiency virus type 1 capsid assembly and infectivity.

Authors:  Samir Abdurahman; Akos Végvári; Masoud Youssefi; Michael Levi; Stefan Höglund; Elin Andersson; Peter Horal; Bo Svennerholm; Jan Balzarini; Anders Vahlne
Journal:  Antimicrob Agents Chemother       Date:  2008-07-21       Impact factor: 5.191

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.